Background: Robotic hepatectomy (RH) is currently widely accepted and it is associated with some benefits when compared to open hepatectomy (OH). However, whether such benefits can still be achieved for patients with large hepatocellular carcinoma (HCC) remain unclear. This study aimed to evaluate the short-term and long-term outcomes of patients undergoing RH or OH. Methods: Perioperative and survival data from patients with large HCC who underwent RH or OH between January 2010 and December 2020 were collected from eight centres. Propensity score matching (PSM) was performed to minimise potential biases. Results: Using predefined inclusion criteria, 797 patients who underwent OH and 309 patients who underwent RH were enroled in this study. After PSM, 280 patients in the robotic group had shorter operative time (median 181 vs. 201 min, P<0.001), lower estimated blood loss (median 200 vs. 400 ml, P<0.001), and shorter postoperative length of stay (median 6 vs. 9 days, P10 cm) who underwent RH had significantly lower estimated blood loss (median 200.0 vs. 500.0 min, P<0.001), and shorter length of stay (median 7 vs. 10 days, P<0.001) than those who underwent OH. Conclusion: Safety and feasibility of RH and OH for patients with large HCC were comparable. RH resulted in similar long-term survival outcomes as OH.
1 October 2020 in Langenbeck's Archives of Surgery
Gastric cancer (GC) is one of the most common and highly lethal malignant tumors worldwide, and its occurrence and development are regulated by multiple molecular mechanisms. Post-translational modifications (PTM) common forms include ubiquitylation, phosphorylation, acetylation and methylation. Emerging research has highlighted lactylation and glycosylation. The diverse realm of PTM and PTM crosstalk is linked to many critical signaling events involved in neoplastic transformation, carcinogenesis and metastasis. This review provides a comprehensive overview of the impact of PTM on the occurrence and progression of GC. Specifically, aberrant PTM have been shown to alter the proliferation, migration, and invasion capabilities of GC cells. Moreover, PTM are closely associated with resistance to chemotherapeutic agents in GC. Notably, this review also discusses the phenomenon of PTM crosstalk, highlighting the interactions among PTM and their roles in regulating signaling pathways and protein functions. Therefore, in-depth investigation into the mechanisms of PTM and the development of targeted therapeutic strategies hold promise for advancing early diagnosis, treatment, and prognostic evaluation of GC, offering novel insights and future research directions.
Long-term inflammatory reaction may promote gastric cancer initiation and development through multiple mechanisms. Recent studies have demonstrated that inflammatory mediators play a crucial role in the transition from gastritis to gastric cancer. Pro-inflammatory cytokines, chemokines, and other signaling molecules interact and synergistically regulate gastric epithelial cell proliferation, apoptosis, migration, and invasiveness, thereby promoting tumorigenesis. Specifically, interleukins activate immune cells, induce the secretion of inflammatory mediators, and maintain local immune responses; however, in the context of cancer, they exhibit a dual role by both enhancing anti-tumor immunity and driving tumor progression. Tumor necrosis factor amplifies immune responses by stimulating the production of pro-inflammatory cytokines, yet excessive or chronic Tumor necrosis factor activity is a hallmark of autoimmune diseases. Interferons initiate antiviral responses, modulate immune cell functions, and influence the inflammatory cascade. Chemokines primarily mediate the recruitment of immune cells to sites of infection, inflammation, or injury, but also play key roles in immune evasion and tumor immune regulation. This review summarizes the cooperative roles of these inflammatory mediators in the progression from gastritis to gastric cancer and discusses their potential as therapeutic targets. A better understanding of these mechanisms may facilitate the development of novel strategies for the prevention and treatment of gastric cancer.
28 January 2025 in Langenbeck's Archives of Surgery